These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35868501)

  • 1. Dual orexin receptor antagonist drug suvorexant can help in amelioration of predictable chronic mild stress-induced hyperalgesia.
    Chavan P; Chikahisa S; Shiuchi T; Shimizu N; Dalanon J; Okura K; Séi H; Matsuka Y
    Brain Res Bull; 2022 Oct; 188():39-46. PubMed ID: 35868501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual orexin receptor blocker suvorexant attenuates hypercapnic ventilatory augmentation in mice.
    Fukushi I; Yokota S; Takeda K; Terada J; Umeda A; Yoshizawa M; Kono Y; Hasebe Y; Onimaru H; Pokorski M; Okada Y
    Brain Res; 2022 Nov; 1795():148061. PubMed ID: 36037880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
    Gentile TA; Simmons SJ; Watson MN; Connelly KL; Brailoiu E; Zhang Y; Muschamp JW
    Neuropsychopharmacology; 2018 Apr; 43(5):1001-1009. PubMed ID: 28741623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans.
    Stoops WW; Strickland JC; Hatton KW; Hays LR; Rayapati AO; Lile JA; Rush CR
    Pharmacol Biochem Behav; 2022 Oct; 220():173466. PubMed ID: 36152876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
    Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW
    Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
    Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
    Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
    Prajapati SK; Krishnamurthy S
    Behav Brain Res; 2021 Feb; 399():113015. PubMed ID: 33212086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of descending pain control system regulated by orexin receptor signaling in the induction of central post-stroke pain in mice.
    Matsuura W; Nakamoto K; Tokuyama S
    Eur J Pharmacol; 2020 May; 874():173029. PubMed ID: 32084419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
    Tsuneki H; Kon K; Ito H; Yamazaki M; Takahara S; Toyooka N; Ishii Y; Sasahara M; Wada T; Yanagisawa M; Sakurai T; Sasaoka T
    Endocrinology; 2016 Nov; 157(11):4146-4157. PubMed ID: 27631554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain sensitivity increases with sleep disturbance under predictable chronic mild stress in mice.
    Dalanon J; Chikahisa S; Shiuchi T; Shimizu N; Chavan P; Suzuki Y; Okura K; Séi H; Matsuka Y
    Sci Rep; 2021 Jul; 11(1):14231. PubMed ID: 34244555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orexin contributes to eupnea within a critical period of postnatal development.
    Spinieli RL; Ben Musa R; Kielhofner J; Cornelius-Green J; Cummings KJ
    Am J Physiol Regul Integr Comp Physiol; 2021 Oct; 321(4):R558-R571. PubMed ID: 34405704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The analgesic effect of orexin-A in a murine model of chemotherapy-induced neuropathic pain.
    Toyama S; Shimoyama N; Shimoyama M
    Neuropeptides; 2017 Feb; 61():95-100. PubMed ID: 28041630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
    Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
    J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of suvorexant.
    Stahl SM
    CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suvorexant: first global approval.
    Yang LP
    Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
    Sun H; Palcza J; Card D; Gipson A; Rosenberg R; Kryger M; Lines C; Wagner JA; Troyer MD
    J Clin Sleep Med; 2016 Jan; 12(1):9-17. PubMed ID: 26194728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
    Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
    Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
    J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.